Literature DB >> 19711133

Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma.

Amir A Ghaferi1, Sandra L Wong, Timothy M Johnson, Lori Lowe, Alfred E Chang, Vincent M Cimmino, Carol R Bradford, Riley S Rees, Michael S Sabel.   

Abstract

PURPOSE: Sentinel lymph node (SLN) biopsy provides important prognostic information for patients with cutaneous melanoma. There may be additional prognostic significance to melanoma spreading from the SLN to nonsentinel lymph nodes (NSLN). We examined the implications of a positive NSLN for overall and distant disease-free survival.
METHODS: Using a prospectively maintained, Institutional Review Board-approved melanoma database we studied patients who had a cutaneous melanoma, a positive SLN, and a completion lymph node dissection (CLND). Survival was determined using a combination of hospital records and the Social Security Death Index (SSDI). Univariate and multivariate Cox regression analysis was performed to further characterize predictors of overall and distant disease-free survival. Kaplan-Meier analysis was used to generate survival curves.
RESULTS: A total of 429 patients with positive SLN biopsies were identified, with at least one positive NSLN identified in 71 (17%). Median follow-up time was 36.8 months. Presence of a positive NSLN was significantly associated with poor outcome, although long-term survival was possible. Presence of ulceration, high mitotic rate, angiolymphatic invasion, total number of positive nodes, and volume of disease>1% in the SLN were significant predictors of survival on univariate analysis, but lost significance on multivariate. Multivariate Cox analysis revealed several predictors of overall survival: increasing age [hazard ratio (HR) 1.04, P<0.01], Breslow depth (HR 1.76, P<0.01), presence of extracapsular extension in the SLN (HR 2.39, P<0.01), and positive NSLN (HR 1.92, P<0.01).
CONCLUSION: Among node-positive melanoma patients, presence of a positive NSLN is a highly significant poor prognostic sign, even after considering the total number of positive nodes and volume of disease in the SLN. CLND after a positive SLN provides this important prognostic information.

Entities:  

Mesh:

Year:  2009        PMID: 19711133     DOI: 10.1245/s10434-009-0665-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

1.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Shouluan Ding; David R Byrd; Natale Cascinelli; Alistair J Cochran; Daniel G Coit; Alexander M Eggermont; Timothy Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

2.  Nodal and systemic recurrence following observation of a positive sentinel lymph node in melanoma.

Authors:  E K Bartlett; A Y Lee; P M Spanheimer; D M Bello; M S Brady; C E Ariyan; D G Coit
Journal:  Br J Surg       Date:  2020-06-02       Impact factor: 6.939

3.  Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system.

Authors:  Anna M Leung; Donald L Morton; Junko Ozao-Choy; Danielle M Hari; Myung Shin-Sim; Andrew L Difronzo; Mark B Faries
Journal:  JAMA Surg       Date:  2013-09       Impact factor: 14.766

Review 4.  Significance of sentinel lymph node biopsy in malignant melanoma: overview of international data.

Authors:  Yoichi Moroi
Journal:  Int J Clin Oncol       Date:  2009-12-05       Impact factor: 3.402

5.  Nonsentinel node metastases in melanoma: do they reflect the biology of the tumor, the lymph node or the surgeon? : Editorial to Accompany Ghaferi et al., ASO-2009-03-0312.R1.

Authors:  Vernon K Sondak
Journal:  Ann Surg Oncol       Date:  2009-08-11       Impact factor: 5.344

6.  Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden.

Authors:  Piotr Rutkowski; Zbigniew I Nowecki; Alexander C J van Akkooi; Jadwiga Kulik; Michej Wanda; Janusz A Siedlecki; Alexander M M Eggermont; Wlodzimierz Ruka
Journal:  Ann Surg Oncol       Date:  2010-07-07       Impact factor: 5.344

7.  Prediction of sentinel node status and clinical outcome in a melanoma centre.

Authors:  Vera Teixeira; Ricardo Vieira; Inês Coutinho; Rita Cabral; David Serra; Maria José Julião; Maria Manuel Brites; Anabela Albuquerque; João Pedroso de Lima; Américo Figueiredo
Journal:  J Skin Cancer       Date:  2013-12-25

8.  The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique.

Authors:  Piotr Rutkowski; Konrad Szydłowski; Zbigniew I Nowecki; Maciej Sałamacha; Tomasz Goryń; Beata Mitręga-Korab; Andrzej Pieńkowski; Wirginiusz Dziewirski; Marcin Zdzienicki
Journal:  World J Surg Oncol       Date:  2015-10-13       Impact factor: 2.754

9.  Recent Evolution in the Management of Lymph Node Metastases in Melanoma.

Authors:  Shelby Breit; Elise Foley; Elizabeth Ablah; Hayrettin Okut; Joshua Mammen
Journal:  Kans J Med       Date:  2021-03-19

10.  Inflammation and tumor microenvironment in lymph node metastasis.

Authors:  Xuesong Wu; Tomonori Takekoshi; Ashley Sullivan; Sam T Hwang
Journal:  Cancers (Basel)       Date:  2011-03-01       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.